The achievement of a 3-month complete cytogenetic response to second-generation tyrosine Kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure

Elias Jabbour, Hagop Kantarjian, Hady Ghanem, Susan O'Brien, Alfonso Quintas-Cardama, Guillermo Garcia-Manero, Marylou Cardenas, Jorge Cortes

Research output: Contribution to journalArticle

16 Scopus citations


Background: We assessed whether the achievement of a 3-month complete cytogenetic response (CCyR) in 123 patients with chronic myeloid leukemia (CML) in the chronic phase, which was treated with second-generation tyrosine kinase inhibitors (2nd-TKI) after imatinib failure could predict for survival. Patients and Methods: In a multivariate analysis, the lack of a 3-month CCyR to 2nd-TKI therapy was selected as the only independent factor associated with poor event-free survival (hazard ratio [HR] 4.5; P <.001) and overall survival (5.4; P =.03). Results: The 3-year event-free survival and overall survival rates were 74% and 43%, respectively, for patients with 3-month CCyR, and were 98% and 79%, respectively, for patients without 3-month CCyR. In a multivariate analysis, high hemoglobin level, previous major cytogenetic response to imatinib therapy, and ≤90% Philadelphia-positive metaphases were associated with the achievement of a 3-month CCyR. Conclusion: The achievement of a 3-month CCyR is the only predictor of outcome in patients treated with 2nd-TKI therapy after imatinib failure. Patients with <3-month CCyR may not obtain long-term benefit and should be followed-up closely.

Original languageEnglish (US)
Pages (from-to)302-306
Number of pages5
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number3
Publication statusPublished - Jun 1 2013
Externally publishedYes



  • Chronic myeloid leukemia
  • Cytogenetic response
  • Prognosis
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this